*Doses are commonly-reported figures from public sources, not a recommendation. Educational only.
| Year | Title / venue | Source |
|---|---|---|
| 2012 | Menorrhagia BMJ clinical evidence · preclinical | PMID 22305976 |
| 2011 | Breast pain BMJ clinical evidence · preclinical | PMID 21477394 |
| 2010 | Endometriosis BMJ clinical evidence · preclinical | PMID 21418683 |
| 2010 | Breast cancer (metastatic) BMJ clinical evidence · preclinical | PMID 21418674 |
| 2008 | Menorrhagia BMJ clinical evidence · preclinical | PMID 19445802 |
| 2007 | Endometriosis BMJ clinical evidence · preclinical | PMID 19454060 |
| 2007 | Breast pain BMJ clinical evidence · preclinical | PMID 19454068 |
| 2007 | Premenstrual syndrome BMJ clinical evidence · preclinical | PMID 19454075 |
| 2007 | Breast cancer (metastatic) BMJ clinical evidence · preclinical | PMID 19454050 |
| 1999 | Gonadorelin-induced testosterone release: a biological assay for quality assurance of gonadorelin in veterinary medicine Drug development and industrial pharmacy · preclinical | PMID 10071824 |
| 1983 | Gonadorelin--synthetic LH-RH The Medical letter on drugs and therapeutics · preclinical | PMID 6358816 |
| 1981 | Gonadorelin and erythropoiesis Archives of internal medicine · preclinical | PMID 7006547 |
Gonadorelin (Gonadorelin (synthetic GnRH)). Synthetic form of GnRH. Pulsatile administration stimulates physiologic LH/FSH; continuous administration paradoxically downregulates the axis.
Commonly discussed uses: diagnostic pituitary testing, fertility induction (pulsatile), HPTA support adjunct (off-label/anecdotal in TRT context). There is both human and animal/preclinical research, though the depth and quality vary by indication. Note: most uses are not approved indications.
Mechanism: Synthetic form of GnRH. Pulsatile administration stimulates physiologic LH/FSH; continuous administration paradoxically downregulates the axis.
Reported considerations: headache, flushing, injection-site reaction, rare hypersensitivity/anaphylaxis. There is both human and animal/preclinical research, though the depth and quality vary by indication. Prescription medicine. Off-label HPTA-support use should be physician-directed; listed here as reference. This is not a safety endorsement; safety data for unapproved compounds is incomplete.
Commonly cited ranges (educational reference, not a recommendation): low diagnostic 100mcg, typical pulsatile clinical dosing, high protocol-defined. Administration: subcutaneous, intravenous, pulsatile pump. Half-life: 2-10 minutes.
Australian status: Prescription-only. Prescription medicine. Off-label HPTA-support use should be physician-directed; listed here as reference. General regulatory context: most active peptides are Schedule 4 and require a prescription; import via the Personal Importation Scheme requires a valid Australian prescription for prescription-only goods.
Reconstitution/storage reference: per registered product / compounded vial varies; storage: refrigerated.
Commonly discussed combinations (anecdotal for unapproved compounds): clinical: standalone under specialist; anecdotal TRT-adjunct use is off-label. Stacking increases interaction/safety uncertainty.